These risks and uncertainties include , but are not limited to : the risk that ADVENTRX 's common stock will be delisted by the NYSE Amex , including as a result of failing to comply with applicable stockholder approval requirements or failing to maintain sufficient stockholders ' equity or a sufficient stock price ; the risk that the provisions of Delaware General Corporation Law will prohibit ADVENTRX from making the dividend and other payments due its 5 % Series B convertible preferred stock ( or to the holders thereof ) , which may be a breach of its certificate of incorporation or other contractual obligations and expose ADVENTRX to corresponding liability ; the risk that ADVENTRX will be unable to raise sufficient additional capital on a timely basis to submit an NDA for ANX-530 , to fund operations , including pre-launch activities , during the FDA review period , if an NDA is submitted , or to conduct launch activities , should an NDA for ANX-530 be approved ; the risk that ADVENTRX will be unable to raise sufficient additional capital on a timely basis to continue as a going concern ; the risk that ADVENTRX will seek protection under the provisions of the U.S. Bankruptcy Code ; the risk that ADVENTRX will reassess the results of the ANX-530 bioequivalence study and determine to conduct additional bioequivalence studies of ANX-530 , including in humans ; the potential for regulatory authorities to require additional preclinical work and / or clinical activities to support regulatory filings , including prior to the submission or the approval of an NDA for ANX-530 , which activities may increase the cost and timeline to NDA submission or approval ; the risk the FDA will determine that ANX-530 and Navelbine ( R ) are not bioequivalent , including as a result of performing pharmacokinetic equivalence analysis based on a patient population other than the population on which ADVENTRX based its analysis ; difficulties or delays in manufacturing , obtaining regulatory approval for and marketing ANX-530 , including validating commercial manufacturing processes and manufacturers , as well as suppliers ; the risk that ADVENTRX will trigger a " maintenance failure " under that certain Rights Agreement , dated July 27 , 2005 , as amended , and be required to pay liquidated damages , including as a result of losing its eligibility to use Form S-3 if its common stock is delisted from the NYSE Amex ; and other risks and uncertainties more fully described in ADVENTRX 's press releases and in the prospectus supplement that was filed with the Securities and Exchange Commission on June 30 , 2009 .